---
title: "Gilead CEO Daniel O'Day disposes of USD 2.23 million in common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297824805.md"
description: "Gilead Sciences CEO Daniel O'Day sold 14,000 common shares on September 1, 2026, valued at approximately USD 2.23 million. The transaction price ranged from $147.51 to $149.38 per share. Following this sale, his directly held stake decreased to 577,133 shares. This information was published via EDGAR by Gilead Sciences."
datetime: "2026-09-02T20:13:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297824805.md)
  - [en](https://longbridge.com/en/news/297824805.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297824805.md)
generator: "portal-rs"
---

# Gilead CEO Daniel O'Day disposes of USD 2.23 million in common shares

-   Gilead Sciences Chairman and CEO Daniel Patrick O’Day sold 14,000 common shares on Sep. 1, 2026. \* Sales priced at about $147.51 to $149.38 per share. \* Directly held stake fell to 577,133 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001638643-26-000031), on September 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)

## Related News & Research

- [Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth](https://longbridge.com/en/news/298621247.md)
- [HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir](https://longbridge.com/en/news/298763671.md)
- [Assembly Bio highlights Phase 2 starts for ABI-6250, GS-1179 in pipeline update](https://longbridge.com/en/news/298359938.md)
- [Apogee Enterprises director Julie K. Streich files initial beneficial ownership statement](https://longbridge.com/en/news/299090386.md)
- [Arrive AI CFO Piyush Phadke files initial beneficial ownership statement](https://longbridge.com/en/news/299115075.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**